• Kahr RasmussenNiklasN0009-0005-0607-6617Medical & Science Innovation, Novo Nordisk A/S, Søborg, Denmark., Birgitte Berg, Anne Sia Louise Christiansen, Jesper Skov Neergaard, Gitte Ter-Borch, Emily A Hildebrand, Maya Gonczi, and Thomas Sparre.
• Medical & Science Innovation, Novo Nordisk A/S, Søborg, Denmark.
• Patient Prefer Adher. 2024 Jan 1; 18: 171317271713-1727.

IntroductionConcizumab is a once-daily prophylactic treatment developed for patients with hemophilia A or B (HA/HB) with or without inhibitors. It is the first treatment for hemophilia patients to be delivered subcutaneously using a pre-filled, multi-dose pen-injector with a 4 mm, 32 G needle.AimTo investigate patient and caregiver handling and preference for the concizumab pen-injector compared with current injection systems used to treat hemophilia.MethodsThis preference and handling study was conducted in accordance with authority guidelines for approval of new devices and included adults and adolescents with HA/HB with or without inhibitors and caregivers currently administering factor replacement therapy or factor VIII mimetic (emicizumab) therapy. All participants underwent a training session, followed by a test session during which participants independently administered a single pen-injection into an injection pad or manikin. Time to train, time to prepare and inject, and number of complete independent injections handling the pen were assessed. Participants evaluated handling and preference via the Hemophilia Device Handling and Preference Assessment Questionnaire.Results80 participants (44 adults, 21 adolescents, 15 caregivers) currently using factor replacement therapy (n=41, 51%) or emicizumab (n=39, 49%) participated. Average training time and time to complete an injection were 7 min 49s and 1 min 21s. In total, 98% of independent complete injections were achieved at first attempt. 98% (n=78; 95% confidence interval [CI] 91-100%) of participants assessed the pen-injector as either "easy" or "very easy" to use. 88% of participants preferred the pen-injector (n=70; 95% CI 78-94%) over their current injection system, and 9% (n=7) reported "no preference".ConclusionParticipants found the concizumab pen-injector easy to learn and easy to use and preferred it over their current injection systems.© 2024 Kahr Rasmussen et al.

5 keywords...

hide…